|Description:||The YMRS is the most frequently used scale for assessing symptoms of mania in patients diagnosed with or being screened for bipolar disorder. The scale has 11 items and is based on the patient’s self-report of his or her condition over the previous 48 hours.|
|Disease States:||Bipolar disorder|
|Validated Uses:||Screening, Symptom Severity|
|Time to administer:||16–30 minutes|
|Commonly used in:||Clinical Trials & Research|
|Detailed Description:||The YMRS is an 11-item scale.1,8 Seven items are ranked on a scale of 0–4 (elevated mood, increased motor activity/energy, sexual interest, reduction in sleep, language/thought disorder, poor appearance, lack of insight).1,8 Four items are ranked on a scale of 0–8 (irritability, rate and amount of speech, thought content, disruptive/aggressive behavior).1,8 Intermediate or half point ratings can be assigned in patients for whom symptom severity falls between two defined anchor points.1,8 The total score ranges from 0 (none) to 60 (most severe).8 A YMRS score > 20 is commonly used as inclusion criteria in clinical trials for bipolar disorder.2 When used for tracking symptom progression over time, a difference of 6–7 points on the YMRS is thought to be clinically significant.2|
|Scale Validity:||Duplicate ratings of 35 patients with manic symptoms demonstrate that inter-rater reliability of the YMRS is high, ranging from 0.66 to 0.95 depending on the item.1|
|Alternative Versions:||The YMRS has been modified for use in pediatric and adolescent populations.9,10 A parent-report adaptation of the Young Mania Rating Scale (commonly known as the P-YMRS) was designed to be completed by parents.9,10|
|Cited Limitations:||The YMRS is not comprehensive and does not evaluate all possible manifestations of mania.5 Some symptoms of mania that are not addressed include distractibility, increases in goal-directed activity, and excessive involvement in pleasurable yet risky activities.5|
Supporting references for the filters are as follows:
Disease States: Bipolar disorder1,2; Validated Uses: Screening3, Symptom Severity1,4,5; Populations: Adult1,3,6; Administration Method: Clinician-report1,3; Time to administer: 16–30 minutes1,5; Commonly used in: Clinical Trials & Research2,5,7,8
- Young, RC et al. Br J Psychiatry. 1978;133:429-435.
- Lukasiewicz, M et al. Int J Methods Psychiatr Res. 2013;22(1):46-58.
- Beidas, RS et al. Cogn Behav Pract. 2015;22(1):5-19.
- Rush, AJ et al. Handbook of Psychiatric Measures. (American Psychiatric Publishing, Inc., 2008).
- Miller, CJ et al. Clin Psychol (New York). 2009;16(2):188-201.
- Tohen, M et al. Clinical trial design challenges in mood disorders. (Elsevier Inc., 2015).
- Rucci, P et al. J Psychopathology. 2013;19:143-159.
- Goldstein, G et al. Handbook of Psychological Assessment. 4th edn (Elsevier, 2020).
- Youngstrom, EA et al. J Clin Child Adolesc Psychol. 2002;31(4):567-572.
- Youngstrom, E et al. Bipolar Disord. 2005;7(6):507-517.